Selecta Biosciences To Accelerate Program for Novel Dual Action Vaccine For Malaria

Grant from the Bill & Melinda Gates Foundation to Leverage Synthetic Nanoparticle Vaccine Platform to Enable Potent, Durable, Dual-Action Vaccines June 17, 2014 Selecta Biosciences, a¬†clinical stage¬†biotechnology company developing a novel class of targeted antigen-specific immune therapies, announced today that it has been awarded a $1.25 million grant from the Bill & Melinda Gates Foundation. The grant supports the research …

Fingerprint Scanning Leads to Improved Vaccination Rates in West Africa

lumidigm multispectral imaging fingerprint sensors have now been installed at 31 clinics across southern Benin, West Africa. These scanners were developed in coordination with VaxTrac, and through a combination of the latest vaccine record keeping software and lumidigm’s fingerprint sensors, the hope is that vaccine waste can be decreased from the 50% found in many regions, whilst increasing the number …

GSK, Sanofi Pasteur partner with Gates Foundation to accelerate vaccine R&D

GlaxoSmithKline and Sanofi Pasteur have each announced a partnership with the Bill & Melinda Gates Foundation (BMGF) through the newly created Vaccine Discovery Partnership (VxDP). The VxDP is a BMGF initiative that aims to drive advances in vaccine R&D through collaboration with vaccine-pharmaceutical companies, biotechnology institutions, NGOs and academia. The partnership with GSK will focus on research into vaccine thermostability, …